EA201792545A1 - Способы и наборы для лечения депрессии - Google Patents

Способы и наборы для лечения депрессии

Info

Publication number
EA201792545A1
EA201792545A1 EA201792545A EA201792545A EA201792545A1 EA 201792545 A1 EA201792545 A1 EA 201792545A1 EA 201792545 A EA201792545 A EA 201792545A EA 201792545 A EA201792545 A EA 201792545A EA 201792545 A1 EA201792545 A1 EA 201792545A1
Authority
EA
Eurasian Patent Office
Prior art keywords
depression
kits
methods
treatment
treating depression
Prior art date
Application number
EA201792545A
Other languages
English (en)
Inventor
Джаскаран Сингх
Иво Каэрс
Элла Дали
Уэйн С. Дриветс
Original Assignee
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Нв filed Critical Янссен Фармацевтика Нв
Publication of EA201792545A1 publication Critical patent/EA201792545A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)

Abstract

Настоящее изобретение относится, в частности, к способам и наборам для лечения депрессии (предпочтительно устойчивой к лечению депрессии) или для лечения депрессии у пациентов с суицидальными наклонностями и/или для лечения и/или профилактики суицидального поведения (например, вынашивания идеи самоубийства), включающим прием эскетамина в соответствии с определенными режимами дозирования.
EA201792545A 2015-05-20 2016-05-20 Способы и наборы для лечения депрессии EA201792545A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562164026P 2015-05-20 2015-05-20
PCT/US2016/033404 WO2016187491A1 (en) 2015-05-20 2016-05-20 Methods and kits for treating depression

Publications (1)

Publication Number Publication Date
EA201792545A1 true EA201792545A1 (ru) 2018-05-31

Family

ID=57320901

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792545A EA201792545A1 (ru) 2015-05-20 2016-05-20 Способы и наборы для лечения депрессии

Country Status (20)

Country Link
US (1) US20160338977A1 (ru)
EP (1) EP3297618A4 (ru)
JP (1) JP2018515557A (ru)
KR (1) KR20180008634A (ru)
CN (1) CN107735081A (ru)
AU (3) AU2016263598A1 (ru)
CA (1) CA2986477A1 (ru)
CL (1) CL2017002904A1 (ru)
CO (1) CO2017011564A2 (ru)
DO (1) DOP2017000268A (ru)
EA (1) EA201792545A1 (ru)
EC (1) ECSP17077930A (ru)
GT (1) GT201700246A (ru)
HK (1) HK1252937A1 (ru)
IL (1) IL255463A (ru)
MA (1) MA42135A (ru)
MX (1) MX2017014797A (ru)
PE (1) PE20180260A1 (ru)
PH (1) PH12017502103A1 (ru)
WO (1) WO2016187491A1 (ru)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014240102A1 (en) 2013-03-15 2015-09-17 Janssen Pharmaceutica Nv Pharmaceutical composition of S-ketamine hydrochloride
CA2957926A1 (en) 2014-08-13 2016-02-18 Janssen Pharmaceutica Nv Method for the treatment of depression
MA40620A (fr) 2014-09-15 2016-03-24 Janssen Pharmaceutica Nv Régimes posologiques spécifiques au génotype val66met (snp rs6265) et méthodes pour le traitement de la dépression
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
EP3297620A4 (en) 2015-06-27 2019-01-09 Shenox Pharmaceuticals, LLC TRANSDERMAL DELIVERY SYSTEM FOR KETAMINE
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
CN117531017A (zh) * 2017-12-22 2024-02-09 詹森药业有限公司 用于治疗抑郁症的艾司氯胺酮
CN112188889A (zh) 2018-06-27 2021-01-05 克雷西奥生物科技有限公司 治疗重度抑郁症的方法
EP3628313A1 (en) * 2018-09-28 2020-04-01 Celon Pharma S.A. Ketamine composition for use in a method of treatment of depression by pulmonary administration
KR20210074275A (ko) 2018-10-05 2021-06-21 클렉시오 바이오사이언시스 리미티드 주요 우울 장애를 치료하기 위한 에스케타민의 복용 요법
WO2020070547A1 (en) * 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
WO2020070706A1 (en) * 2018-10-05 2020-04-09 Clexio Biosciences Ltd. Dosage regime of esketamine for treating major depressive disorder
EP3863617A1 (en) * 2018-10-11 2021-08-18 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
MA55218A (fr) * 2019-03-05 2022-01-12 Janssen Pharmaceuticals Inc Eskétamine pour le traitement de la dépression
US20220304950A1 (en) * 2019-08-28 2022-09-29 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of patients with major depressive disorder, including suicidality
TW202135787A (zh) 2019-12-12 2021-10-01 比利時商健生藥品公司 艾氯胺酮調配物及製備與儲存的方法
IL293506A (en) 2019-12-30 2022-08-01 Clexio Biosciences Ltd Dosage regimen with escitamine for the treatment of clinical depression
GB202019952D0 (en) * 2020-12-17 2021-02-03 Neurocentrx Pharma Ltd Novel compositions
WO2022235576A1 (en) * 2021-05-03 2022-11-10 Wang Michael Z Methods and compositions for treating depression

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007229866A1 (en) * 2006-03-22 2007-10-04 Mount Sinai School Of Medicine Intranasal administration of ketamine to treat depression
WO2013138322A1 (en) * 2012-03-12 2013-09-19 Janssen Pharmaceutica Nv Esketamine for the treatment of treatment-refractory or treatment-resistant depression
EP2983787B1 (en) * 2013-04-12 2019-10-02 Icahn School of Medicine at Mount Sinai Method for treating post-traumatic stress disorder
MA40620A (fr) * 2014-09-15 2016-03-24 Janssen Pharmaceutica Nv Régimes posologiques spécifiques au génotype val66met (snp rs6265) et méthodes pour le traitement de la dépression

Also Published As

Publication number Publication date
US20160338977A1 (en) 2016-11-24
MA42135A (fr) 2018-03-28
AU2021215155A1 (en) 2021-09-02
PE20180260A1 (es) 2018-02-05
ECSP17077930A (es) 2018-02-28
CN107735081A (zh) 2018-02-23
HK1252937A1 (zh) 2019-06-06
PH12017502103A1 (en) 2018-05-07
CL2017002904A1 (es) 2018-04-20
CA2986477A1 (en) 2016-11-24
KR20180008634A (ko) 2018-01-24
EP3297618A4 (en) 2019-01-23
CO2017011564A2 (es) 2018-04-19
DOP2017000268A (es) 2018-04-15
AU2016263598A1 (en) 2017-11-23
AU2016263598A8 (en) 2017-11-30
AU2023237026A1 (en) 2023-10-12
GT201700246A (es) 2019-07-29
MX2017014797A (es) 2018-02-15
WO2016187491A1 (en) 2016-11-24
JP2018515557A (ja) 2018-06-14
IL255463A (en) 2018-01-31
EP3297618A1 (en) 2018-03-28

Similar Documents

Publication Publication Date Title
EA201792545A1 (ru) Способы и наборы для лечения депрессии
CY1125144T1 (el) Φαρμακευτικη συνθεση, μεθοδοι θεραπειας και χρηση αυτης
EA201691877A1 (ru) Человеческие антитела к спайк-белку коронавируса ближневосточного респираторного синдрома
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EA201790142A1 (ru) Лечение лейкоза ингибиторами гистондеацетилазы
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
EA201790195A1 (ru) Способы лечения рака с применением ингибиторов tigit и противораковых агентов
EA201692511A1 (ru) Комбинированное лечение ингибиторами глутаминазы
BR112019001737A2 (pt) expressão de pten-long com vírus oncolíticos
EA201692285A8 (ru) Ингибиторы ezh2 для лечения лимфомы
BR112014012607A2 (pt) métodos de tratamento usando um inibidor de interferon gama
EA201792182A1 (ru) Композиции и способы для лечения анемии
MA40620A (fr) Régimes posologiques spécifiques au génotype val66met (snp rs6265) et méthodes pour le traitement de la dépression
BR112017021312A2 (pt) tratamento de câncer de pulmão com inibidores de glutaminase
EA201591543A1 (ru) Комбинированные терапии для лечения рака с применением микрорнк и ингибиторов egfr-tki
MX2020010269A (es) Un anticuerpo anti-il-23p 19 (mirikizumab) para usarse en el tratamiento de la colitis ulcerosa.
BR112018001853A2 (pt) métodos para tratamento de um distúrbio e para melhoria do tratamento de um distúrbio
MX2018016057A (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
EA201790787A1 (ru) Снижение вязкости фармацевтических составов
EA201892287A1 (ru) Фармацевтические комбинации для лечения рака
EA201891664A1 (ru) Составы/композиции, содержащие ингибитор btk
EA201792641A1 (ru) Ингибитор оси igfbp3/tmem219 и диабет
EA201891527A1 (ru) Композиции и способы обнаружения и лечения рака пищевода
MX2018001369A (es) Combinaciones de inhibidores de tirosina quinasa de bruton y sus usos.
UY38352A (es) Inhibidores de integrina alfavbeta6